Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN C MORRIS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1407055700
CMS profile
199093
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$47.41

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $27.34 2
Food and Beverage $20.07 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $27.34 2
Pinnacle Biologics, Inc $20.07 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN C MORRIS

NPI 1407055700 · CMS profile ID 199093

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1407055700?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN C MORRIS, NPI 1407055700, CMS profile ID 199093. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1407055700?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JOHN C MORRIS, NPI 1407055700, CMS profile ID 199093. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1407055700?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JOHN C MORRIS, NPI 1407055700, CMS profile ID 199093, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1407055700?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $47.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $11.2008/03/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727857895 CMS
E.R. Squibb & Sons, L.L.C. $16.1407/13/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727857887 CMS
Pinnacle Biologics, Inc $20.0702/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713613079 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $16,237.63 14
PY2020 $47.41 3
PY2021 $15.09 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $9,079.64 11
PY2021 Principal investigator $145,254.08 61
PY2020 Principal investigator $619,634.54 405
PY2019 Recipient $2,196.32 22
PY2019 Principal investigator $597,649.00 78

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

405 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 EMD Serono, Inc. $50.18 12/31/2020 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586541
Principal investigator 1 EMD Serono, Inc. $61.00 12/31/2020 Non-covered Recipient Entity
UC Health LLC.
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587205
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,839.00 12/28/2020 Non-covered Recipient Entity
University of Cincinnati
Phase III Stage III Unresectable NSCLC Combo No dispute reported 06/30/2026 753820939
Principal investigator 1 EMD Serono, Inc. $650.00 12/15/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749600051
Principal investigator 1 EMD Serono, Inc. $1,580.00 12/15/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749608423
Principal investigator 1 EMD Serono, Inc. $2,222.00 12/15/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749611727
Principal investigator 1 EMD Serono, Inc. $2,541.00 12/15/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749612999
Principal investigator 1 F. Hoffmann-La Roche AG $517.01 12/15/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
1L NSCLC DX ALL COMER SQUAMOUS No dispute reported 06/30/2026 743179763
Principal investigator 1 F. Hoffmann-La Roche AG $327.60 12/08/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
1L NSCLC DX ALL COMER SQUAMOUS No dispute reported 06/30/2026 743179749
Principal investigator 1 EMD Serono, Inc. $948.00 12/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603201
Principal investigator 1 EMD Serono, Inc. $1,008.00 12/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604247
Principal investigator 1 EMD Serono, Inc. $50.18 11/30/2020 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586547
Principal investigator 1 EMD Serono, Inc. $61.00 11/30/2020 Non-covered Recipient Entity
UC Health LLC.
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587209
Principal investigator 1 EMD Serono, Inc. $1,337.00 11/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749606701
Principal investigator 1 EMD Serono, Inc. $1,762.00 11/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749609485
Principal investigator 1 EMD Serono, Inc. $2,664.00 11/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749613411
Principal investigator 1 EMD Serono, Inc. $3,555.00 11/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749615915
Principal investigator 1 F. Hoffmann-La Roche AG $575.00 11/05/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
1L NSCLC DX ALL COMER NON SQUAMOUS No dispute reported 06/30/2026 743179775
Principal investigator 1 F. Hoffmann-La Roche AG $3,000.00 11/05/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
1L NSCLC DX ALL COMER NON SQUAMOUS No dispute reported 06/30/2026 743179785
Principal investigator 1 EMD Serono, Inc. $628.00 11/03/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749599237
Principal investigator 1 EMD Serono, Inc. $948.00 11/03/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603381
Principal investigator 1 EMD Serono, Inc. $948.00 11/03/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603385
Principal investigator 1 EMD Serono, Inc. $1,008.00 11/03/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604249
Principal investigator 1 EMD Serono, Inc. $50.18 10/30/2020 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586557
Principal investigator 1 EMD Serono, Inc. $61.00 10/30/2020 Non-covered Recipient Entity
UC Health LLC.
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587213
Principal investigator 1 EMD Serono, Inc. $325.00 10/20/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749594991
Principal investigator 1 EMD Serono, Inc. $759.00 10/20/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749601705
Principal investigator 1 EMD Serono, Inc. $1,660.00 10/20/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609103
Principal investigator 1 EMD Serono, Inc. $1,762.00 10/16/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749609489
Principal investigator 1 EMD Serono, Inc. $2,233.00 10/16/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749611751
Principal investigator 1 EMD Serono, Inc. $2,881.00 10/16/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749614783
Principal investigator 1 Merck Sharp & Dohme Corporation $6,174.00 10/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER
A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer No dispute reported 06/30/2026 740786205
Principal investigator 1 EMD Serono, Inc. $948.00 10/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603389
Principal investigator 1 EMD Serono, Inc. $948.00 10/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603393
Principal investigator 1 EMD Serono, Inc. $948.00 10/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603397
Principal investigator 1 EMD Serono, Inc. $948.00 10/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603401
Principal investigator 1 EMD Serono, Inc. $948.00 10/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603405
Principal investigator 1 EMD Serono, Inc. $3,030.00 10/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749615193
Principal investigator 1 EMD Serono, Inc. $635.20 10/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749616171
Principal investigator 1 EMD Serono, Inc. $50.18 09/30/2020 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586511
Principal investigator 1 EMD Serono, Inc. $61.00 09/30/2020 Non-covered Recipient Entity
UC Health LLC.
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587147
Principal investigator 1 EMD Serono, Inc. $2,538.00 09/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749612987
Principal investigator 1 EMD Serono, Inc. $4,209.00 09/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749616197
Principal investigator 1 EMD Serono, Inc. $2,014.00 09/17/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749611017
Principal investigator 1 EMD Serono, Inc. $2,538.00 09/17/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749612993
Principal investigator 1 EMD Serono, Inc. $4,209.00 09/17/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749616199
Principal investigator 1 EMD Serono, Inc. $4,335.00 09/17/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749616245
Principal investigator 1 EMD Serono, Inc. $4,335.00 09/17/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749616247
Principal investigator 1 EMD Serono, Inc. $5,601.00 09/17/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749616673
Principal investigator 1 EMD Serono, Inc. $948.00 09/03/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603329
Principal investigator 1 EMD Serono, Inc. $948.00 09/03/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603335
Principal investigator 1 EMD Serono, Inc. $948.00 09/03/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603339
Principal investigator 1 EMD Serono, Inc. $1,008.00 09/03/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604373
Principal investigator 1 EMD Serono, Inc. $1,008.00 09/03/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604376
Principal investigator 1 EMD Serono, Inc. $1,008.00 09/03/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604379
Principal investigator 1 EMD Serono, Inc. $30,020.50 09/03/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749618079
Principal investigator 1 EMD Serono, Inc. $2,700.00 09/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749613471
Principal investigator 1 EMD Serono, Inc. $3,038.00 09/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749615197
Principal investigator 1 EMD Serono, Inc. $50.18 08/31/2020 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586517
Principal investigator 1 EMD Serono, Inc. $61.00 08/31/2020 Non-covered Recipient Entity
UC Health LLC.
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587161
Principal investigator 1 AbbVie Inc. $22,714.00 08/20/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
M19-700 No dispute reported 06/30/2026 721181619
Principal investigator 1 EMD Serono, Inc. $1,604.00 08/20/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749608644
Principal investigator 1 EMD Serono, Inc. $3,464.00 08/20/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749615815
Principal investigator 1 EMD Serono, Inc. $4,335.00 08/20/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749616243
Principal investigator 1 EMD Serono, Inc. $5,601.00 08/20/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749616675
Principal investigator 1 EMD Serono, Inc. $3,062.50 08/20/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749617317
Principal investigator 1 EMD Serono, Inc. $703.00 08/18/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749600673
Principal investigator 1 Genentech, Inc. $1,041.30 08/13/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC No dispute reported 06/30/2026 743179907
Principal investigator 1 Merck Sharp & Dohme Corporation $7,378.80 08/12/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI MEDICAL CENTER
A Phase III Randomized Trial of MK-3475 Versus Standard Treatment in Subjects with recurrent or metastatic head and neck cancer No dispute reported 06/30/2026 740786203
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593351
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593355
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593359
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593363
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593367
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593371
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593375
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593377
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593381
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593385
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593389
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593393
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593401
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593404
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593407
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593412
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593417
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593421
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593426
Principal investigator 1 EMD Serono, Inc. $250.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593431
Principal investigator 1 EMD Serono, Inc. $440.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749596309
Principal investigator 1 EMD Serono, Inc. $440.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749596313
Principal investigator 1 EMD Serono, Inc. $440.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749596317
Principal investigator 1 EMD Serono, Inc. $440.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749596321
Principal investigator 1 EMD Serono, Inc. $440.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749596325
Principal investigator 1 EMD Serono, Inc. $440.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749596329
Principal investigator 1 EMD Serono, Inc. $440.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749596333
Principal investigator 1 EMD Serono, Inc. $440.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749596337
Principal investigator 1 EMD Serono, Inc. $3,016.00 08/06/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749615159
Principal investigator 1 EMD Serono, Inc. $50.18 07/31/2020 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586525
Principal investigator 1 EMD Serono, Inc. $61.00 07/31/2020 Non-covered Recipient Entity
UC Health LLC.
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587191
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594625
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594629
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594633
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594637
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594641
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594645
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594651
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594655
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594657
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594661
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594666
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594669
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594673
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594677
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594681
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594685
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594689
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594693
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594697
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594701
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594705
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594709
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594713
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594717
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594721
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594723
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594727
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594731
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594735
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594739
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594743
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594747
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594749
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594751
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594755
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594759
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594763
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594767
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594771
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594775
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594779
Principal investigator 1 EMD Serono, Inc. $318.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749594783
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599633
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599635
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599639
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599643
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599649
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599653
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599657
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599661
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599665
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599669
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599673
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599677
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599681
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599685
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599689
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599693
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599697
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599701
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599705
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599707
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599711
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599715
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599719
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599721
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599725
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599729
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599733
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599739
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599743
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599747
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599749
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599755
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599759
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599763
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599767
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599771
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599775
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599779
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599783
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599787
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599791
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599795
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599799
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599803
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599807
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599811
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599815
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599819
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599823
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599827
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599831
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599835
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599839
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599843
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599847
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599851
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599855
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599861
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599865
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599869
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599873
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599877
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599881
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599885
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599889
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599893
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599897
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599899
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599903
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599907
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599911
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599915
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599921
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599925
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599929
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599933
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599936
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599941
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599945
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599949
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599951
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599955
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599960
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599965
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599969
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599975
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599979
Principal investigator 1 EMD Serono, Inc. $645.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749599983
Principal investigator 1 EMD Serono, Inc. $756.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749601609
Principal investigator 1 EMD Serono, Inc. $2,624.90 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749613269
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
1L NSCLC DX ALL COMER NON SQUAMOUS No dispute reported 06/30/2026 743179863
Principal investigator 1 F. Hoffmann-La Roche AG $5,665.40 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
1L NSCLC DX ALL COMER NON SQUAMOUS No dispute reported 06/30/2026 743179873
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 07/23/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
1L NSCLC DX ALL COMER NON SQUAMOUS No dispute reported 06/30/2026 743179883
Principal investigator 1 EMD Serono, Inc. $948.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603343
Principal investigator 1 EMD Serono, Inc. $948.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603347
Principal investigator 1 EMD Serono, Inc. $948.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603351
Principal investigator 1 EMD Serono, Inc. $948.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603357
Principal investigator 1 EMD Serono, Inc. $1,008.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604383
Principal investigator 1 EMD Serono, Inc. $1,008.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604387
Principal investigator 1 EMD Serono, Inc. $1,008.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604391
Principal investigator 1 EMD Serono, Inc. $2,014.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749611021
Principal investigator 1 EMD Serono, Inc. $2,014.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749611025
Principal investigator 1 EMD Serono, Inc. $3,555.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749615913
Principal investigator 1 EMD Serono, Inc. $5,601.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749616677
Principal investigator 1 EMD Serono, Inc. $7,158.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749617107
Principal investigator 1 EMD Serono, Inc. $7,158.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749617109
Principal investigator 1 EMD Serono, Inc. $7,158.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749617111
Principal investigator 1 EMD Serono, Inc. $7,461.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749617161
Principal investigator 1 EMD Serono, Inc. $7,461.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749617163
Principal investigator 1 EMD Serono, Inc. $7,461.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749617165
Principal investigator 1 EMD Serono, Inc. $7,461.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749617167
Principal investigator 1 EMD Serono, Inc. $8,425.00 07/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination with Avelumab with and without Palliative Radiotherapy in Participants with Selected Advanced Solid Tumors No dispute reported 06/30/2026 749617299
Principal investigator 1 EMD Serono, Inc. $948.00 07/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603361
Principal investigator 1 EMD Serono, Inc. $948.00 07/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603365
Principal investigator 1 EMD Serono, Inc. $948.00 07/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603369
Principal investigator 1 EMD Serono, Inc. $948.00 07/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603373
Principal investigator 1 EMD Serono, Inc. $948.00 07/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603377
Principal investigator 1 EMD Serono, Inc. $1,008.00 07/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604395
Principal investigator 1 EMD Serono, Inc. $1,008.00 07/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604399
Principal investigator 1 EMD Serono, Inc. $50.18 06/30/2020 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586507
Principal investigator 1 EMD Serono, Inc. $61.00 06/30/2020 Non-covered Recipient Entity
UC Health LLC.
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587121
Principal investigator 1 EMD Serono, Inc. $1,539.00 06/18/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749608215
Principal investigator 1 EMD Serono, Inc. $3,836.00 06/18/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749616055
Principal investigator 1 EMD Serono, Inc. $703.00 06/17/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749600669
Principal investigator 1 EMD Serono, Inc. $654.00 06/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749600071
Principal investigator 1 EMD Serono, Inc. $703.00 06/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749600700
Principal investigator 1 EMD Serono, Inc. $703.00 06/01/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749600705
Principal investigator 1 EMD Serono, Inc. $50.18 05/29/2020 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586495
Principal investigator 1 EMD Serono, Inc. $61.00 05/29/2020 Non-covered Recipient Entity
UC Health LLC.
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587103
Principal investigator 1 EMD Serono, Inc. $628.00 05/26/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749599233
Principal investigator 1 EMD Serono, Inc. $759.00 05/26/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749601701
Principal investigator 1 EMD Serono, Inc. $948.00 05/26/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603317
Principal investigator 1 EMD Serono, Inc. $948.00 05/26/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603321
Principal investigator 1 EMD Serono, Inc. $948.00 05/26/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603325
Principal investigator 1 EMD Serono, Inc. $1,008.00 05/26/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604235
Principal investigator 1 EMD Serono, Inc. $1,560.00 05/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749608339
Principal investigator 1 EMD Serono, Inc. $2,981.00 05/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749614979
Principal investigator 1 EMD Serono, Inc. $948.00 05/14/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603299
Principal investigator 1 EMD Serono, Inc. $948.00 05/14/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603303
Principal investigator 1 EMD Serono, Inc. $948.00 05/14/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603307
Principal investigator 1 EMD Serono, Inc. $948.00 05/14/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603313
Principal investigator 1 EMD Serono, Inc. $1,008.00 05/14/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604349
Principal investigator 1 EMD Serono, Inc. $1,008.00 05/14/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604353
Principal investigator 1 EMD Serono, Inc. $1,008.00 05/14/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604357
Principal investigator 1 EMD Serono, Inc. $15,051.00 05/14/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749617753
Principal investigator 1 F. Hoffmann-La Roche AG $6,320.34 05/12/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
1L NSCLC DX ALL COMER NON SQUAMOUS No dispute reported 06/30/2026 743180101
Principal investigator 1 EMD Serono, Inc. $50.18 04/30/2020 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586491
Principal investigator 1 EMD Serono, Inc. $61.00 04/30/2020 Non-covered Recipient Entity
UC Health LLC.
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749587037
Principal investigator 1 EMD Serono, Inc. $313.00 04/27/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749594483
Principal investigator 1 EMD Serono, Inc. $840.00 04/27/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749602349
Principal investigator 1 EMD Serono, Inc. $1,660.00 04/27/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609119
Principal investigator 1 EMD Serono, Inc. $1,660.00 04/27/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609123
Principal investigator 1 EMD Serono, Inc. $221.00 04/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749592341
Principal investigator 1 EMD Serono, Inc. $313.00 04/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749594479
Principal investigator 1 EMD Serono, Inc. $325.00 04/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749594953
Principal investigator 1 EMD Serono, Inc. $1,420.00 04/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749607421
Principal investigator 1 EMD Serono, Inc. $1,539.00 04/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749608211
Principal investigator 1 EMD Serono, Inc. $1,660.00 04/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609099
Principal investigator 1 EMD Serono, Inc. $1,986.00 04/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749610627
Principal investigator 1 EMD Serono, Inc. $3,975.00 04/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749616131
Principal investigator 1 EMD Serono, Inc. $3,975.00 04/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749616133
Principal investigator 1 EMD Serono, Inc. $4,120.00 04/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749616185
Principal investigator 1 EMD Serono, Inc. $4,505.00 04/21/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749616303
Principal investigator 1 EMD Serono, Inc. $293.60 04/20/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749600027
Principal investigator 1 EMD Serono, Inc. $1,000.00 04/20/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749603859
Principal investigator 1 EMD Serono, Inc. $1,300.00 04/20/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749606561
Principal investigator 1 EMD Serono, Inc. $948.00 04/14/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603291
Principal investigator 1 EMD Serono, Inc. $948.00 04/14/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603295
Principal investigator 1 EMD Serono, Inc. $338.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749595111
Principal investigator 1 EMD Serono, Inc. $732.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749601095
Principal investigator 1 EMD Serono, Inc. $792.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749601951
Principal investigator 1 EMD Serono, Inc. $799.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749602051
Principal investigator 1 EMD Serono, Inc. $843.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749602353
Principal investigator 1 EMD Serono, Inc. $948.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603261
Principal investigator 1 EMD Serono, Inc. $948.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603265
Principal investigator 1 EMD Serono, Inc. $948.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603269
Principal investigator 1 EMD Serono, Inc. $948.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603273
Principal investigator 1 EMD Serono, Inc. $948.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603277
Principal investigator 1 EMD Serono, Inc. $948.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603281
Principal investigator 1 EMD Serono, Inc. $948.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603287
Principal investigator 1 EMD Serono, Inc. $1,008.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604333
Principal investigator 1 EMD Serono, Inc. $1,008.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604337
Principal investigator 1 EMD Serono, Inc. $1,008.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604341
Principal investigator 1 EMD Serono, Inc. $1,008.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604345
Principal investigator 1 EMD Serono, Inc. $2,500.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749612613
Principal investigator 1 EMD Serono, Inc. $3,375.00 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749615739
Principal investigator 1 EMD Serono, Inc. $5,017.00 04/09/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749616521
Principal investigator 1 EMD Serono, Inc. $5,152.00 04/09/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749616563
Principal investigator 1 EMD Serono, Inc. $5,827.00 04/09/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749616731
Principal investigator 1 EMD Serono, Inc. $8,217.40 04/09/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749617691
Principal investigator 1 EMD Serono, Inc. $41,156.80 04/09/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749618029
Principal investigator 1 EMD Serono, Inc. $50.18 03/31/2020 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586481
Principal investigator 1 EMD Serono, Inc. $61.00 03/31/2020 Non-covered Recipient Entity
UC Health LLC.
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749586955
Principal investigator 1 F. Hoffmann-La Roche AG $6,415.11 03/17/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI
1L NSCLC DX ALL COMER NON SQUAMOUS No dispute reported 06/30/2026 743179851
Principal investigator 1 EMD Serono, Inc. $150.00 03/16/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749591539
Principal investigator 1 EMD Serono, Inc. $7,920.00 03/16/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749617247
Principal investigator 1 EMD Serono, Inc. $948.00 03/13/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603251
Principal investigator 1 EMD Serono, Inc. $948.00 03/13/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603257
Principal investigator 1 EMD Serono, Inc. $1,008.00 03/13/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604231
Principal investigator 1 EMD Serono, Inc. $5,250.00 03/13/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749616581
Principal investigator 1 EMD Serono, Inc. $250.00 03/12/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593221
Principal investigator 1 EMD Serono, Inc. $250.00 03/12/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593237
Principal investigator 1 EMD Serono, Inc. $250.00 03/12/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593241
Principal investigator 1 EMD Serono, Inc. $250.00 03/12/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593244
Principal investigator 1 EMD Serono, Inc. $250.00 03/12/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749593247
Principal investigator 1 EMD Serono, Inc. $440.00 03/12/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749596299
Principal investigator 1 EMD Serono, Inc. $1,660.00 03/12/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609095
Principal investigator 1 Genentech, Inc. $2,527.20 03/12/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC No dispute reported 06/30/2026 743179895
Principal investigator 1 EMD Serono, Inc. $92.38 03/11/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749591101
Principal investigator 1 EMD Serono, Inc. $1,300.00 03/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749606593
Principal investigator 1 EMD Serono, Inc. $1,300.00 03/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749606597
Principal investigator 1 EMD Serono, Inc. $3,250.00 03/02/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749615567
Principal investigator 1 EMD Serono, Inc. $50.18 02/28/2020 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586477
Principal investigator 1 EMD Serono, Inc. $61.00 02/28/2020 Non-covered Recipient Entity
UC Health LLC.
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749586951
Principal investigator 1 EMD Serono, Inc. $313.00 02/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749594529
Principal investigator 1 EMD Serono, Inc. $313.00 02/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749594531
Principal investigator 1 EMD Serono, Inc. $325.00 02/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749594949
Principal investigator 1 EMD Serono, Inc. $759.00 02/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749601693
Principal investigator 1 EMD Serono, Inc. $840.00 02/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749602345
Principal investigator 1 EMD Serono, Inc. $1,660.00 02/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609109
Principal investigator 1 EMD Serono, Inc. $1,660.00 02/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609111
Principal investigator 1 EMD Serono, Inc. $1,660.00 02/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609115
Principal investigator 1 EMD Serono, Inc. $3,836.00 02/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological ad clinical activity of MSB0010718C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications. No dispute reported 06/30/2026 749616053
Principal investigator 1 EMD Serono, Inc. $799.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749602055
Principal investigator 1 EMD Serono, Inc. $799.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749602059
Principal investigator 1 EMD Serono, Inc. $799.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749602063
Principal investigator 1 EMD Serono, Inc. $948.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603205
Principal investigator 1 EMD Serono, Inc. $948.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603209
Principal investigator 1 EMD Serono, Inc. $948.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603211
Principal investigator 1 EMD Serono, Inc. $948.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603217
Principal investigator 1 EMD Serono, Inc. $948.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603221
Principal investigator 1 EMD Serono, Inc. $948.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603225
Principal investigator 1 EMD Serono, Inc. $948.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603231
Principal investigator 1 EMD Serono, Inc. $948.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603235
Principal investigator 1 EMD Serono, Inc. $948.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603241
Principal investigator 1 EMD Serono, Inc. $948.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603245
Principal investigator 1 EMD Serono, Inc. $948.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749603247
Principal investigator 1 EMD Serono, Inc. $1,008.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604299
Principal investigator 1 EMD Serono, Inc. $1,008.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604303
Principal investigator 1 EMD Serono, Inc. $1,008.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604305
Principal investigator 1 EMD Serono, Inc. $1,008.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604313
Principal investigator 1 EMD Serono, Inc. $1,008.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604317
Principal investigator 1 EMD Serono, Inc. $1,008.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604321
Principal investigator 1 EMD Serono, Inc. $1,008.00 02/19/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
An Open-Label, Multicenter Follow-up Study to Collect Long-Term Data on Participant from Multiple Avelumab (MSB0010718C) Clinical Studies No dispute reported 06/30/2026 749604329
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 02/05/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
AN OPEN-LABEL, PHASE 1B/2 STUDY INVESTIGATING RECOMMENDED PHASE 2 DOSE, SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF TAK-659 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) No dispute reported 06/30/2026 737069935
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $390.00 02/05/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
AN OPEN-LABEL, PHASE 1B/2 STUDY INVESTIGATING RECOMMENDED PHASE 2 DOSE, SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF TAK-659 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) No dispute reported 06/30/2026 737069937
Principal investigator 1 EMD Serono, Inc. $50.18 01/31/2020 Non-covered Recipient Entity
University of Cincinnati Cancer Institute
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586473
Principal investigator 1 EMD Serono, Inc. $61.00 01/31/2020 Non-covered Recipient Entity
UC Health LLC.
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749586947
Principal investigator 1 EMD Serono, Inc. $660.00 01/28/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749600159
Principal investigator 1 EMD Serono, Inc. $1,300.00 01/28/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749606555
Principal investigator 1 EMD Serono, Inc. $1,444.00 01/28/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749607501
Principal investigator 1 EMD Serono, Inc. $759.00 01/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749601695
Principal investigator 1 EMD Serono, Inc. $1,660.00 01/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609091
Principal investigator 1 EMD Serono, Inc. $1,707.00 01/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749609319
Principal investigator 1 EMD Serono, Inc. $2,532.00 01/24/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors with expansion to selected indications. No dispute reported 06/30/2026 749612983
Principal investigator 1 F. Hoffmann-La Roche AG $936.00 01/24/2020 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
1L NSCLC DX ALL COMER SQUAMOUS No dispute reported 06/30/2026 743177747
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,187.80 01/22/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
AN OPEN-LABEL, PHASE 1B/2 STUDY INVESTIGATING RECOMMENDED PHASE 2 DOSE, SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF TAK-659 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) No dispute reported 06/30/2026 737068225
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,188.54 01/15/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI BARRETT CANCER CENTER
A PHASE III, MULTICENTER, RANDOMZIED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF CANAKINUMAB (IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL ALONE IN PATIENTS WITH NON-SMALL CELL LUNG CANCER PREVIOUSLY TREATED WITH PD(L)- No dispute reported 06/30/2026 721496847
Principal investigator 1 F. Hoffmann-La Roche AG $1,000.00 01/14/2020 Non-covered Recipient Entity
UNIV OF CINCINNATI PHYSICIANS
1L NSCLC DX ALL COMER SQUAMOUS No dispute reported 06/30/2026 743177729
Principal investigator 1 EMD Serono, Inc. $49.00 01/08/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586374
Principal investigator 1 EMD Serono, Inc. $49.00 01/08/2020 Non-covered Recipient Entity
UNIVERSITY OF CINCINNATI PHYSICIANS
A Phase II single-arm trial to investigate tepotinib in advanced (Stage IIIb and IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations or MET amplification (VISION) No dispute reported 06/30/2026 749586377
Principal investigator 1 EMD Serono, Inc. $200.00 01/07/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749592177
Principal investigator 1 EMD Serono, Inc. $245.00 01/07/2020 Non-covered Recipient Entity
UC HEALTHCARE SYSTEM
A Phase Ib study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination with M9241(NHS-IL12) (JAVELIN IL-12) No dispute reported 06/30/2026 749592493